Ascletis Pharma, Inc. ( (HK:1672) ) has issued an announcement.
Ascletis Pharma Inc. announced positive results from its Phase Ib study of ASC30, a small molecule oral GLP-1 receptor agonist, which showed significant body weight reduction in participants with obesity. The study supports a ‘lower starting dose and slower titration’ strategy for the upcoming Phase IIa study, which has been submitted to the FDA, indicating potential advancements in obesity treatment and reinforcing Ascletis’s position in the pharmaceutical industry.
More about Ascletis Pharma, Inc.
Ascletis Pharma Inc. is a biopharmaceutical company focused on developing innovative drugs for the treatment of liver diseases, viral infections, and cancer. The company is known for its in-house discovery and development of small molecule drugs, including the investigational GLP-1 receptor agonist ASC30 for obesity treatment.
YTD Price Performance: 64.12%
Average Trading Volume: 7,165,545
Technical Sentiment Signal: Sell
Current Market Cap: HK$4.78B
See more insights into 1672 stock on TipRanks’ Stock Analysis page.